Pharmaceutical company Esperion Therapeutics, Inc. is dedicated to developing and commercializing innovative treatments for patients with elevated low density lipoprotein cholesterol. Its two lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets, aimed at treating those with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. In a bid to enhance their portfolio, the company has entered into a license and collaboration agreement with Daiichi Sankyo Europe GmbH and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Founded in 2008, Esperion Therapeutics, Inc. is based in Ann Arbor, Michigan.
Esperion Therapeutics's ticker is ESPR
The company's shares trade on the NASDAQ stock exchange
They are based in Ann Arbor, Michigan
There are 11-50 employees working at Esperion Therapeutics
It is esperion.com
Esperion Therapeutics is in the Healthcare sector
Esperion Therapeutics is in the Biotechnology industry
The following five companies are Esperion Therapeutics's industry peers: